November 12, 2012 — Boston Scientific Corp. and the University of Rochester Medical Center presented positive results from the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT) clinical trial that demonstrated improved programming of Boston Scientific dual-chamber implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D) heart devices can reduce inappropriate therapy and risk of death.
November 12, 2012 — Intrinsic Medical Imaging (IMI) introduced its Matrix Volumetric Analytics software for advanced anatomical interrogation at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) conference held Oct. 23 to 26 in Miami. The technology enables assessment of vascular and heart structure pre- and post-surgery for a wide variety of procedures.
Results from the POSEIDON Trial were presented at Transcatheter Cardiovascular Therapeutics (TCT) 2012. Data showed a ...
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
The PC Trial data presented at TCT 2012 looked at transcather PFO closure vs. medical therapy in preventing cryptogenic ...
More than 350,000 deaths occur each year as a result of sudden cardiac arrest (SCA), which occurs when the heart abruptly and unexpectedly stops beating. A survey issued by the Heart Rhythm Society (HRS) shows a lack of awareness of SCA and the treatment options. In fact, 75 percent of Americans are unaware that an implantable cardioverter defibrillator (ICD) is an effective treatment option to protect those at risk of SCA. In October, HRS highlights SCA Awareness Month with its annual "Apples and Oranges" campaign to raise awareness for SCA and help educate the general public about risk factors and life-saving therapies.
November 9, 2012 — Boston Scientific Corp. has received approval to update the directions for use (DFU) labeling for Promus Element and Promus Element Plus coronary drug eluting stent (DES) systems to include three-month dual antiplatelet therapy (DAPT).
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
November 9, 2012 — Svelte Medical Systems announced it received conditional approval from the U.S. Food and Drug Administration (FDA) to begin a pivotal study for the Svelte coronary stent integrated delivery system (IDS).
November 9, 2012 — The U.S. Food and Drug Administration (FDA) recently cleared Bolton Medical’s Relay Thoracic Stent Graft with Plus Delivery System.
November 9, 2012 — A study found that the use of rosuvastatin prior to angioplasty did not influence the levels of troponin I, a sensitive indicator of muscle damage. Results were presented at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
November 9, 2012 — Bristol-Myers Squibb Co. and Pfizer Inc. announced that the reductions in stroke or systemic embolism, major bleeding, and mortality demonstrated with Eliquis compared to warfarin in the ARISTOTLE trial were consistent across a wide range of stroke and bleeding risk scores in patients with nonvalvular atrial fibrillation. These results of a subanalysis from the ARISTOTLE clinical trial were published in The Lancet.
Toshiba’s advanced radiation dose reduction technology, Adaptive Iterative Dose Reduction 3D (AIDR 3D), is now available ...
Toshiba will showcase Spot Fluoro, a dose management tool for Infinix-i vascular X-ray systems. Spot Fluoro allows clinicians to view a region of anatomy using live fluoroscopy while viewing the Last Image Hold surrounding area, resulting in lower dose and a larger image display area than offered by previous technology.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
November 8, 2012 — Results of the RESPECT clinical trial, presented at TCT 2012, indicates that using an investigational medical device to close a PFO, or “hole in the heart,” may be superior to medical management alone in the prevention of a repeated stroke.
November 8, 2012 — A hydration regimen tailored to the patient’s fluid status was effective in reducing damage to kidneys in patients undergoing cardiac catheterization, according to a study presented at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.
November 8, 2012 — A U.S. Food and Drug Administration (FDA) advisory committee is meeting Dec. 5 to discuss how to classify and regulate intra-aortic balloon pumps (IABPs), which have been grandfathered without clear policy since the FDA tightened regulations on medical devices in the late 1970s. The panel will also discuss classifications for two other grandfathered technologies, including external counter-pulsating (ECP) devices and cardiopulmonary bypass blood pumps.